BioCryst (BCRX) Q2 FY26 earnings call

BioCryst Pharmaceuticals delivered a strong Q2 FY26, driven by robust ORLADEYO performance and a significant upfront payment from a navenibart licensing deal. The company is strategically shifting its R&D focus to external innovation, aiming to build a balanced pipeline of rare disease assets while maintaining a strong financial position. Key clinical programs, including navenibart and BCX17725, are advancing as planned, with the pediatric ORLADEYO launch exceeding early expectations.